Display options
Cite
Calfee JE. Can quality-adjusted life year avoidance help in oncology drug reimbursement decisions?. J Oncol Pract. 2008;4(1):8doi: 10.1200/JOP.0711501.
Calfee, J. E. (2008). Can quality-adjusted life year avoidance help in oncology drug reimbursement decisions?. Journal of oncology practice, 4(1), 8. https://doi.org/10.1200/JOP.0711501
Calfee, John E. "Can quality-adjusted life year avoidance help in oncology drug reimbursement decisions?." Journal of oncology practice vol. 4,1 (2008): 8. doi: https://doi.org/10.1200/JOP.0711501
Calfee JE. Can quality-adjusted life year avoidance help in oncology drug reimbursement decisions?. J Oncol Pract. 2008 Jan;4(1):8. doi: 10.1200/JOP.0711501. PMID: 20859437; PMCID: PMC2793928.
Copy Download .nbib Format: NLM
Share it on

J Oncol Pract. 2008 Jan;4(1):8. doi: 10.1200/JOP.0711501.

Can quality-adjusted life year avoidance help in oncology drug reimbursement decisions?.

Journal of oncology practice

John E Calfee

PMID: 20859437 PMCID: PMC2793928 DOI: 10.1200/JOP.0711501

[No abstract available.]

References

  1. BMJ. 2000 Nov 25;321(7272):1300-1 - PubMed
  2. Health Aff (Millwood). 2003 Jan-Feb;22(1):125-37 - PubMed
  3. Health Aff (Millwood). 2006 Sep-Oct;25(5):1302-8 - PubMed
  4. J Oncol Pract. 2008 Jan;4(1):2-7 - PubMed

Publication Types